Previous Article | Next Article 
Molecular and Cellular Biology, March 1999, p. 2155-2168, Vol. 19, No. 3
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Different Regulation of the p53 Core Domain
Activities 3'-to-5' Exonuclease and Sequence-Specific DNA
Binding
Friedemann
Janus,1
Nils
Albrechtsen,1
Uwe
Knippschild,1
Lisa
Wiesmüller,1
Frank
Grosse,2 and
Wolfgang
Deppert1,*
Heinrich-Pette-Institut für
Experimentelle Virologie und Immunologie an der Universität
Hamburg, D-20251 Hamburg,1 and
Institut für Molekulare Biotechnologie,
Jena,2 Germany
Received 27 March 1998/Returned for modification 7 May
1998/Accepted 8 December 1998
 |
ABSTRACT |
In this study we further characterized the 3'-5' exonuclease
activity intrinsic to wild-type p53. We showed that this activity, like
sequence-specific DNA binding, is mediated by the p53 core domain.
Truncation of the C-terminal 30 amino acids of the p53 molecule
enhanced the p53 exonuclease activity by at least 10-fold, indicating
that this activity, like sequence-specific DNA binding, is negatively
regulated by the C-terminal basic regulatory domain of p53. However,
treatments which activated sequence-specific DNA binding of p53, like
binding of the monoclonal antibody PAb421, which recognizes a
C-terminal epitope on p53, or a higher phosphorylation status, strongly
inhibited the p53 exonuclease activity. This suggests that at least on
full-length p53, sequence-specific DNA binding and exonuclease
activities are subject to different and seemingly opposing regulatory
mechanisms. Following up the recent discovery in our laboratory that
p53 recognizes and binds with high affinity to three-stranded DNA
substrates mimicking early recombination intermediates (C. Dudenhoeffer, G. Rohaly, K. Will, W. Deppert, and L. Wiesmueller, Mol.
Cell. Biol. 18:5332-5342), we asked whether such substrates might be
degraded by the p53 exonuclease. Addition of Mg2+ ions to
the binding assay indeed started the p53 exonuclease and promoted rapid
degradation of the bound, but not of the unbound, substrate, indicating
that specifically recognized targets can be subjected to exonucleolytic
degradation by p53 under defined conditions.
 |
INTRODUCTION |
The best-studied molecular activity
of the tumor suppressor p53 probably is that of a sequence-specific
transactivator (3, 9, 19, 28, 44, 69). p53 becomes activated
as a transcription factor under various cellular stress situations,
including genotoxic stress. This leads to transcriptional upregulation
of p53 target genes, which in turn mediate growth arrest or apoptosis
(13, 32, 41). In addition to its transactivator function,
p53 exerts a variety of other biochemical activities involved in DNA
damage recognition and repair, which characterize p53 as a superior
control element in maintaining the integrity of the cell genome
(2, 26, 37, 49). We recently reported that wild-type (wt)
but not mutant p53 exerts a novel intrinsic 3'-5' exonuclease activity (48). Exonucleases are required in a variety of processes
contributing to genomic stability, such as proofreading, mismatch and
nucleotide excision repair, and recombination (31, 39).
Therefore, we hypothesize that p53, through its exonuclease activity,
could be actively involved in such processes, thereby significantly expanding the role of p53 as a "guardian of the genome"
(35).
In this study we further characterized the p53 exonuclease activity and
specifically addressed the question of how this activity is related to
the sequence-specific DNA binding activity of p53. Our previous
experiments had suggested that the p53 intrinsic exonuclease activity
is exerted by the p53 core domain (48), which also mediates
sequence-specific DNA binding by p53 (1, 4, 16, 51, 67). The
localization of two such different activities to the same domain of the
p53 molecule poses the problem of how these activities are regulated,
since one would expect that p53, which regulates transcription in a
sequence-specific manner, would not exert an exonuclease activity. The
p53 core domain has a complex structure, as it is composed of two
alpha-helical loop domains and a beta-sheet domain, compacted via metal
(zinc) binding (6). This is an unusual arrangement for a DNA
binding domain, which so far has been found only in a few
sequence-specific DNA binding proteins, including NF
B
(47). Interestingly, a similar structural arrangement has
been found for the catalytic domain of Escherichia coli
exonuclease III, a multifunctional enzyme exhibiting 3' phosphatase,
endonuclease, and 3'-5' and 5'-3' exonuclease activities
(45). As a working hypothesis, we therefore assumed that the
composite structure of the p53 core domain might allow the execution of
different activities through conformational alterations leading to
slightly different arrangements of its various structural components.
The data presented in this report confirm that the central domain of
wild-type, but not that of mutant, p53 exerts the p53 intrinsic
exonuclease activity. Like sequence-specific DNA binding (22,
24), this exonuclease activity is negatively regulated by the
C-terminal basic regulatory domain of p53. However, treatments activating sequence-specific DNA binding of full-length p53 strongly inhibited its exonuclease activity, indicating that p53 exonuclease and
sequence-specific DNA binding are separate activities of the p53 core
domain, regulated in opposing manners. As C-terminally truncated p53
had at least a 10-fold higher specific exonuclease activity than
full-length p53, we conclude that under appropriate conditions, wt p53
acts as a bona fide exonuclease. Activation of the p53 exonuclease
activity by addition of Mg2+ ions when p53 had bound to a
potential in vivo substrate, a three-stranded DNA mimicking a
recombination intermediate with a single mismatch (8),
resulted in rapid degradation of the bound, but not the unbound,
substrate, which is indicative of the activation of the p53 exonuclease
within a defined enzyme-substrate complex.
Our data are compatible with a model according to which p53 exerts two
complementary functions in maintaining the integrity of the genome. As
its basal function in maintaining genetic stability, p53 participates
actively in repair processes through activities not related to
sequence-specific DNA binding, specifically through its exonuclease
activity (48). At another level of control, cellular stress
activates the functions of p53 generally associated with its role as a
guardian of the genome, namely, growth arrest and apoptosis (34,
35).
(This work was conducted by F. Janus and N. Albrechsten in partial
fulfillment of the requirements for a Ph.D. degree at the University of
Hamburg, Hamburg, Germany.)
 |
MATERIALS AND METHODS |
Bacteria and cells.
Recombinant baculovirus expressing
full-length and fragments of murine wt p53 protein with coding
information for a His6 tag at the N terminus were kindly provided by P. Tegtmeyer (SUNY, Stony Brook) (67). Murine wt and MethA
(7) p53 DNAs coding for amino acids 80 to 280 were inserted
into the pH6EX3 vector and expressed in DH5
bacteria. Simian virus
40 (SV40) large-T-antigen (T-Ag) recombinant baculovirus was kindly
provided by Ellen Fanning (Department of Molecular Biology, Vanderbilt
University, Nashville, Tenn.). Human wt p53 and human oligomerization
mutant 1262 recombinant baculoviruses were kindly provided by John
Jenkins (Cell Proliferation Laboratory, Marie Curie Research Institute,
Oxted, Surrey, United Kingdom).
Protein purification. (i) Immunoaffinity chromatography.
Protein was purified by PAb421 immunoaffinity chromatography as
described previously (48).
(ii) Co2+ metal affinity chromatography.
About
109 High Five insect cells were infected with the
corresponding recombinant baculovirus and harvested at 44 h
postinfection (hpi). Okadaic acid (200 nM) was added as indicated in
Results at 41 hpi. To purify histidine-tagged proteins by
Co2+ metal affinity column chromatography (TALON;
Clontech), cells were lysed by addition of ice-cold lysis buffer (20 mM
Tris-HCl [pH 8.0], 100 mM NaCl, 0.5% [wt/vol] Lubrol, 5 mM
-mercaptoethanol, 2 mM phenylmethylsulfonyl fluoride, 2 mM
Na2S2O5, 50 µg of leupeptin, per
ml, 1% [vol/vol] Trasylol) and rocked for 1 h. Crude lysate was
centrifuged at 200,000 × g for 35 min and incubated
with column material for 45 min. The column material was washed with
buffer A (20 mM Tris-HCl [pH 8.0], 100 mM KCl, 2 mM
-mercaptoethanol) and with 10 mM imidazole in buffer A. Proteins
were eluted with 300 mM imidazole in buffer A, and 1-ml fractions were
collected. The majority of the bound p53 proteins were recovered in
fraction 2 at high purity.
(iii) Ion-exchange and heparin sulfate affinity
chromatographies.
After metal affinity chromatography, the
p531-320 fragment was further purified by anion-exchange
chromatography with UNO Q anion-exchange column or by heparin
sulfate-Sepharose affinity chromatography with an
ÄKTApurifier fast protein liquid chromatography system
(Pharmacia). The p531-320 fragment was purified via Talon metal affinity chromatography as described above, and a >90% pure, exonuclease-active peak fraction was subjected to ion-exchange chromatography. For anion-exchange chromatography, a 1.3-ml UnoQ column
(Bio-Rad) was equilibrated with 5 column volumes of buffer A (20 mM
Tris, 40 mM KCl, 0.1% mercaptoethanol, pH 8.0) and loaded with 100 µg of protein. For cation-exchange chromatography 140 µg of the
TALON-purified p531-320 fragment was loaded onto a 1-ml HiTrap heparin-Sepharose column (Pharmacia) equilibrated with buffer A. The columns were washed with 3 column volumes of buffer A, and the
protein was eluted with a linear salt gradient (40 to 800 mM KCl) at a
flow rate of 2 ml/min. Fractions of 0.5 ml were collected. All
fractions were tested for exonuclease activity, and peak fractions were
analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and Coomassie blue staining.
SDS-PAGE and Western immunoblotting.
Protein fractions were
denatured in SDS sample buffer, separated by SDS-PAGE, and transferred
to a polyvinylidine difluoride membrane. Proteins were detected with
monoclonal antibodies as indicated in Results.
Exonuclease assays.
The 3'-5' exonuclease activity was
measured by filter binding assays as described previously
(48). For inhibition experiments with PAb421 and PAb108, 5 ng to 10 µg of antibody and 150 ng of metal affinity-purified p53
protein were mixed, preincubated for 15 min at 4°C, and tested for
exonuclease activity. Proteolytic digestion was done by addition of a
dilution series of thermolysin from 4 ng (1:50) to 20 pg (1:10,000) to
150 ng of metal affinity-purified p53 in exonuclease reaction buffer
(25 mM Tris [pH 8.5], 10 mM MgCl2, 1 mM dithiothreitol)
and incubation for 15 min at 37°C. 3H-labeled DNA was
added, and the filter binding assay was performed as described above.
Exonuclease III (Boehringer, Mannheim, Germany) with the same
exonucleolytic activity as 150 ng of p53 was used as a control.
Gel mobility shift assay.
Synthetic p21 promoter
oligonucleotides (10) were end labeled by using T4
polynucleotide kinase and [
-32P]ATP, gel purified, and
used as probes in binding reactions after annealing with unlabeled
complementary strand. p53 was purified by metal affinity chromatography
or nuclear extraction (29). 32P-labeled
three-stranded substrates containing an A-G mismatch were prepared as
described previously (8). Binding reactions were carried out
as described previously (8, 22).
 |
RESULTS |
The p53 exonuclease activity is mediated by the p53 core
domain.
In our previous experiments, a bacterial fragment
comprising the p53 core domain (amino acids 80 to 280) was renatured
after SDS-PAGE and was shown to exhibit 3'-5' exonuclease activity
(48). To analyze the structural prerequisites of the p53
exonuclease activity on native p53, we analyzed various deletion
fragments of mouse p53 (see Fig. 3). With the exception of the
bacterial p5380-280 fragments, all of the p53 fragments
were expressed in insect cells infected with the respective recombinant
baculoviruses. Full-length p53 and all p53 fragments were His tagged at
their N termini, which allowed their easy purification via metal
affinity chromatography (see Materials and Methods). Figure
1 shows the purified
baculovirus-expressed p53 proteins and their corresponding exonuclease
profiles. It is evident that all fragments containing the p53 core
domain, as well as the isolated p53 core domain itself, exhibited
exonuclease activity, whereas those fragments not containing the core
domain were exonuclease negative. We conclude that the p53 core domain
mediates exonuclease activity. This conclusion was further
substantiated by comparing the exonuclease activities of the isolated
core domains (amino acids 80 to 280) of wt p53 and MethA mutant p53
(7) (containing the mutations C132F, E168G, and M234I
[11]), which were expressed in bacteria and purified by metal affinity chromatography. Figure 2A and
B show that these fragments were obtained
in high yields and reasonable purity. Whereas the wt p53 core fragment
displayed exonuclease activity (Fig. 2C), the MethA mutant p53 core
domain was devoid of any exonuclease activity (Fig. 2D). This provides
further evidence that structural alterations induced by mutations in
the p53 core domain abolish not only sequence-specific DNA binding of
p53 but also its exonuclease activity, supporting our previous finding (48) that mutant p53 proteins have lost the p53 exonuclease activity. The results of the exonuclease-mapping experiment are summarized in Fig. 3.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 1.
Exonuclease activities of p53 and p53 deletion mutants.
wt p53 and p53 deletion mutants were expressed in High Five insect
cells infected with recombinant baculovirus and purified by metal
affinity chromatography as described in Materials and Methods. Peak
fractions of all proteins were analyzed by SDS-PAGE (A), and 150 ng of
each protein was tested for exonuclease activity by the 3H
filter retention assay (B). Exonuclease III was used as a control. aa,
amino acids. Lane M, markers. Numbers on the left in panel A are
molecular masses in kilodaltons.
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
wt but not mutant p53 core domain is necessary and
sufficient for p53 exonuclease activity. wt (A and C) and MethA (B and
D) p53 core fragments (amino acids 80 to 280) were expressed in
bacteria and purified by metal affinity chromatography. Column
fractions of both proteins were analyzed by SDS-PAGE (A and B) and
tested for exonuclease activity by the 3H filter retention
assay (C and D). Exonuclease III (lane C) was used as a control.
Numbers on the left in panels A and B are molecular masses in
kilodaltons.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Summary of p53 exonuclease activity mapping data. p53
fragments and their corresponding exonuclease activities are shown
schematically. aa, amino acids.
|
|
Binding of SV40 T-Ag to p53 eliminates its exonuclease
activity.
SV40 T-Ag targets p53 in SV40 lytic infection and
cellular transformation by binding to the p53 core domain
(54). This largely eliminates sequence-specific DNA binding
of p53 and its ability to transactivate p53 target genes (5, 27,
42). It was therefore of interest to analyze whether binding of
T-Ag to p53 would also affect the p53 exonuclease activity. If so, this
would provide further and independent evidence that exonuclease
activity and sequence-specific DNA binding of p53 are mediated by the
same catalytic domain. Furthermore, targeting of p53 exonuclease
activity by SV40 T-Ag might provide hints as to a possible in vivo
relevance of this activity (see Discussion).
Insect cells were infected in parallel either with a recombinant
baculovirus encoding SV40 T-Ag or with a virus encoding the p531-320 fragment. The p531-320 fragment was
chosen for complex formation with T-Ag, because this fragment, in
contrast to full-length p53, very effectively and quantitatively forms
a complex with T-Ag in vitro (unpublished observation). After lysis of
the infected cells, the lysate containing the p531-320
fragment was split, and half of it was mixed with the lysate of cells
expressing T-Ag to allow formation of the T-Ag/p531-320
complex. The p531-320 fragment and the
T-Ag/p531-320 complex were purified from the respective
lysates by metal affinity chromatography via the His tag of the
p531-320 fragment (for details, see Materials and Methods). Figure 4A shows the analysis of the
purified p531-320 fragment and of the
T-Ag/p531-320 complex by Western blotting with a
polyclonal antiserum for p53 (panel a) or the T-Ag-specific monoclonal
antibody PAb108 (panel b). This analysis demonstrates that similar
amounts of free p531-320 fragment and of
p531-320 fragment complexed to T-Ag were recovered during
purification and that the complexed p531-320 fragment had
bound a significant amount of T-Ag. Figure 4B shows the Coomassie
blue-stained pattern of fractions of the free p531-320
fragment (panel a) and of this fragment in complex with T-Ag after
metal affinity chromatography and SDS-PAGE (panel b) and the
corresponding exonuclease activities of the p531-320 fragment in the respective fractions (panels c and d). As is evident from Fig. 4B, the free p531-320 fragment had exonuclease
activity (panel c), whereas this fragment in complex with T-Ag was
devoid of exonuclease activity (panel d).

View larger version (39K):
[in this window]
[in a new window]
|
FIG. 4.
SV40 T-Ag inhibits p53 exonuclease activity. High Five
insect cells were infected with recombinant baculovirus coding for the
p531-320 fragment or SV40 T-Ag. Cells were lysed at 44 h pi, and the p531-320-containing lysate was split. One
half was purified by metal affinity chromatography, and the other half
was mixed with SV40 T-Ag-containing lysate and also purified for
His-tagged p531-320 by metal affinity chromatography.
Column fractions of both preparations were analyzed by SDS-PAGE (B,
panels a and b) and Western blotting (A) and tested for exonuclease
activity (B, panels c and d). Numbers on the left in panel B (panels a
and b) are molecular masses in kilodaltons. Lanes M, markers.
|
|
C-terminally truncated p53 exhibits a significantly higher
exonuclease activity than full-length p53.
During our analyses of
p53 fragments for exonuclease activity, we noticed that the
C-terminally truncated p53 fragments seemed to have a higher specific
activity than full-length p53. This was verified by comparing the
kinetics of substrate degradation for full-length p53 and for the
p531-320 fragment. Figure 5A
shows that the p531-320 fragment degraded the input
substrate DNA at a much higher catalytic rate than did full-length p53.
Quantitative evaluation and determination of the specific exonuclease
activities of various full-length p53 preparations and of the
C-terminally truncated p531-320 and p531-360
fragments (Fig. 5B) revealed that full-length p53, regardless of its
mode of purification, had about a 10-times-lower specific exonuclease
activity than the C-terminally truncated p531-320 and
p531-360 fragments. We conclude that the exonuclease
activity of full-length p53 is negatively regulated by the C-terminal
basic domain, as the shortest truncation which strongly enhanced the
p53 exonuclease was a deletion of the C-terminal 30 amino acids
(p531-360 fragment). Interestingly, and in contrast to the
case for sequence-specific DNA binding (16, 63), the oligomerization status of p53 did not influence the p53 intrinsic exonuclease activity. This conclusion is based on the findings that the
oligomerization-defective p531-320 fragment exhibited the
same, activated specific exonuclease activity as the
oligomerization-competent p531-360 fragment and,
conversely, that the full-length oligomerization-defective p53, 1262 (60, 61), had an exonuclease activity similar to that of
oligomerization-competent wt p53.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
p53 exonuclease activity is negatively regulated
by the C-terminal basic regulatory domain. Full-length wt p53 and
p531-320 were tested for exonuclease activity, and their
relative activities were compared in a time course (A). Specific
exonuclease activities were determined for wt p53 purified by
heparin-Sepharose, immunoaffinity, or metal affinity chromatography and
were compared to those of the oligomerization-defective mutant p53 1262 and deletion mutants p531-320 and p531-360 (B).
Standard deviations are indicated by error bars. One unit corresponds
to the degradation of 60 pmol of DNA per 10 min at 37°C. hp53, human
p53.
|
|
Protease treatment of the full-length p53 protein activates
exonuclease activity.
It has been reported that the full-length
p53 molecule is rather unstable but that C-terminal truncation enhances
the stability of p53 (17). To test the possibility that such
an effect might be responsible for the observed higher specific
activity of the C-terminally truncated p53 fragments, we designed a
control experiment which was based on the previously reported finding
that limited proteolytic digestion of p53 with thermolysin
preferentially degrades the N- and C-terminal portions of the p53
molecule, whereas the p53 core fragment is more resistant to
degradation (4). Constant amounts of purified wt p53 were
incubated in parallel with consecutively higher dilutions of
thermolysin and subjected to exonuclease assays. If activation of the
p53 exonuclease results from C-terminal truncation, then protease
treatment at certain thermolysin-to-p53 ratios should lead to higher
exonuclease activities. Figure 6A shows
that incubation of p53 with thermolysin at certain enzyme dilutions
resulted in a significant activation of the p53 exonuclease activity.
Analysis of the p53 fragments generated by thermolysin in a time course experiment (Fig. 6C) shows that thermolysin treatment rapidly generated
lower-migrating forms of p53; these were detected by PAb240, which
reacts with an epitope in the p53 core domain (15, 59, 70),
but not by PAb421, which reacts with a C-terminal epitope of p53
(18, 58, 65), or by PAb242, which reacts with an N-terminal
epitope of p53 (36, 70). This strongly supports the
interpretation that the lower exonuclease activity of full-length p53
compared to C-terminally truncated p53 fragments results from negative
regulation by the C-terminal basic regulatory domain of p53. Note that
incubation of full-length p53 with reaction buffer alone did not affect
the p53 exonuclease activity (Fig. 6A), further demonstrating that this
activity was stable under our assay conditions and that its activation
by protease treatment resulted from C-terminal truncation. Figure 6B
shows a control experiment demonstrating that a comparable protease
treatment of the bacterial exonuclease III reduced rather than
activated its exonuclease activity.

View larger version (48K):
[in this window]
[in a new window]
|
FIG. 6.
Protease treatment of p53 activates its exonucleolytic
activity. (A and B) Wild-type p53 (A) or exonuclease III (Ex. III) (B)
(150 ng) was digested with various amounts of thermolysin (40 U/mg),
ranging from 4 ng to 20 pg. Exonuclease activity was measured after 15 min of digestion. The amount of exonuclease III was chosen to match the
exonuclease activity of 150 ng of wt p53. Incubation of p53 with buffer
alone for 15 min (p53 buffer control) did not affect the p53
exonuclease activity. (C) Western blot analysis of p53 fragments
resulting from thermolysin digestion after 0, 10, 20, and 30 min of
incubation. Digestions were performed with 1 ng of thermolysin,
corresponding to bar 6 in panel A. After 10 min of thermolysin
digestion, lower-migrating forms of p53 were detected with PAb240,
directed against an epitope in the p53 core domain. Those forms could
not be detected with monoclonal antibodies directed against the p53 N
terminus (PAb242) or the p53 C terminus (PAb 421). Numbers on the left
in panel C are molecular masses in kilodaltons.
|
|
Copurification of the exonuclease activity with the
p531-320 fragment.
We previously provided strong
evidence that the exonuclease activity of p53 is intrinsic to the p53
molecule and is not mediated by an exonuclease associating with p53
(48). The finding that C-terminal truncation of p53
activated the p53 exonuclease by a factor of at least 10 allowed us to
address the question of an associated exonuclease by a different
approach: in a preparation of highly purified exonuclease-active
C-terminally truncated p53, an associated exonuclease should be a major
contaminant, which thus should be clearly detectable. Therefore, we
monitored the exonuclease activity of already highly pure
p531-320 protein, purified by metal chelate chromatography,
during subsequent purification steps. The p531-320 fragment
was chosen over the p531-360 fragment because first, it
lacks the oligomerization domain, thereby greatly facilitating further
purification steps due to the absence of p53 protein in different
oligomeric forms, and second, its apparent molecular mass (45 kDa) is
significantly lower than that of full-length p53, which should allow
the easy identification of a copurifying exonuclease. One hundred
micrograms of p531-320 fragment, purified to greater
than 90% homogeneity by metal affinity chromatography (Fig.
7A, panel a, input) was loaded onto a UNO
Q anion-exchange column and eluted by increasing the salt (KCl)
concentration (for details, see Materials and Methods). Analysis of the
protein eluted from the UNO Q column by SDS-PAGE and Coomassie blue
staining (Fig. 7A, panel a) shows that the p531-320 protein
was recovered as a single peak at about 250 mM KCl (fractions 14 to
18). Most of the protein ran as a single band corresponding to the
p531-320 fragment. However, fraction 18 revealed the
presence of another protein with a molecular mass of approximately 60 kDa; a minor portion of the p531-320 fragment eluted at
higher salt concentration (300 mM) and was recovered in fraction 22. Fractions 14 to 18 contained about 85% of the input
p531-320 protein. These fractions also contained the
majority of the input exonuclease activity (Fig. 7A, panel b, fractions
14 to 18). No detectable exonuclease activity was recovered in
fractions not containing the p531-320 protein. The
exonuclease activity was closely proportional to the amount of
p531-320 fragment, as the exonuclease activity of the
p531-320 fragment in lane 10, which was contaminated by a protein with a molecular mass of approximately 60 kDa, was proportional to the amount of p531-320, and was independent of the
contaminating protein. Alternatively, 140 µg of metal
affinity-purified p531-320 (Fig. 7B, panel a, input) was
loaded onto a heparin sulfate affinity column. The p531-320
fragment was again eluted by increasing the salt (KCl) concentration
and was recovered at 200 to 300 mM KCl. Figure 7B, panel a, shows the
analysis of the heparin sulfate-purified p531-320 fragment
by SDS-PAGE and Coomassie blue staining. The p531-320
fragment eluted as a broad peak (fractions 7 to 14), with no detectable
contaminating proteins and recovering 120 µg of the input protein.
Again, the exonuclease activity coeluted with the p531-320
fragment (Fig. 7B, fractions 7 to 14), rendering it extremely unlikely
that this exonuclease activity was due to an associated exonuclease.
Interestingly, the exonuclease activity profile (Fig. 7B, panel b), in
contrast to the protein elution profile (panel a), of the
p531-320 protein showed a broad shoulder, suggesting the
possibility that the p531-320 protein eluted at a higher
salt concentration has a higher specific exonuclease activity than that
eluted at lower salt concentrations.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 7.
Copurification of the p53 exonuclease activity with the
p531-320 fragment. The p531-320 fragment was
first purified by metal affinity chromatography and then further
purified either by anion-exchange chromatography (UNO Q) (A) or by
heparin-Sepharose affinity chromatography (B). p531-320 was
eluted from the columns with a KCl gradient (see Materials and Methods
for details). All fractions were analyzed for exonuclease activity
(panels b), and peak fractions were analyzed by SDS-PAGE and Coomassie
blue staining (panels a). The purity of the input metal
affinity-purified p531-320 protein is shown in panels a,
lanes input. Note that the exonuclease activity copurifies with the
p531-320 protein in all purification schemes. For
quantitative evaluation of these data, see Table 1. Lanes M, markers.
Numbers on the left in panels a are molecular masses in kilodaltons.
|
|
Table
1 summarizes the purification steps
and the specific activities of the recovered p53
1-320
fragment. As expected, the
already highly pure p53
1-320
protein obtained after metal affinity
chromatography had the highest
specific exonuclease activity.
However, the losses in specific
exonuclease activity encountered
during further chromatography were in
the expected range for the
inactivation of such an enzymatic activity.
Opposing regulation of p53 sequence-specific DNA binding and
exonuclease activities. (i) Effects of PAb421.
PAb421 binds to an
epitope within the basic regulatory domain of p53 and was shown to
activate sequence-specific DNA binding of p53 to certain DNA substrates
(22, 23, 29). As both sequence-specific DNA binding and
exonuclease activities are negatively regulated by the basic regulatory
domain of p53, we asked whether and how PAb421 would affect the p53
exonuclease activity compared to sequence-specific DNA binding.
Full-length p53 was incubated with PAb421 or p53-unrelated PAb108 and
subjected to the exonuclease assay. Figure
8A shows that the exonuclease activity of
full-length p53 was strongly inhibited by PAb421 in a
concentration-dependent manner. This inhibition was due to binding of
PAb421 to the p53 molecule, as even the highest concentration of the
unrelated antibody PAb108 had no effect on its exonuclease activity. In
contrast, binding of PAb421 to p53 strongly activated DNA binding of
p53 to the p21 promoter substrate (Fig. 8B). We conclude that the
exonuclease and sequence-specific DNA binding activities of p53 are
regulated in opposing manners, although both activities are negatively
regulated by the basic regulatory domain of p53.

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 8.
PAb421 influences p53 exonuclease and sequence-specific
DNA binding activities in opposite manners. Metal affinity-purified
full-length p53 was incubated with increasing amounts of PAb421 and
tested for exonuclease activity (A, lanes 2 to 7) or sequence-specific
DNA binding (B). p53 was also incubated with a non-p53-specific
antibody (PAb108, specific for SV40 T-Ag) and tested for exonuclease
activity (A, lanes 8 to 13).
|
|
(ii) Influence of phosphorylation status.
p53 is a
phosphoprotein, and there is accumulating evidence that phosphorylation
is an important determinant in regulating p53 functions (12, 14,
20, 40, 57). We therefore asked whether and how the
phosphorylation status of p53 would influence the p53 exonuclease
activity compared to sequence-specific DNA binding. The phosphorylation
status of a phosphoprotein is determined by the net result of kinase
and phosphatase reactions. Therefore, the phosphorylation status of p53
can be enhanced by inhibiting the activity of phosphatase 2A (PP2A) in
infected insect cells with the PP2A inhibitor okadaic acid. A similar
approach recently was applied to analyze the influence of an enhanced
phosphorylation status of rat p53 on its sequence-specific DNA binding
activity (14).
Insect cells were infected with baculovirus encoding full-length p53.
Half of the cells were kept in normal growth medium,
and the other half
were treated with 200 nM okadaic acid at 41
hpi. Cells were harvested
at 44 hpi, and p53 from both infections
was purified by metal affinity
chromatography (for details, see
Materials and Methods). Purified p53
proteins obtained from the
untreated and the okadaic acid-treated
infections (Fig.
9A) were
analyzed in
parallel for exonuclease activity and for sequence-specific
DNA binding
in electrophoretic mobility shift assays (EMSA), using
the p21 promoter
substrate. Figure
9B shows that p53 from the
untreated infection
displayed exonuclease activity. In contrast,
p53 obtained from the
okadaic acid-treated infection was exonuclease
negative. Conversely,
p53 from untreated cells showed only a low
affinity for the p21
promoter substrate in EMSA, whereas p53 from
okadaic acid-treated cells
was highly active in this assay, even
in the absence of activating
antibody PAb421 (Fig.
9C [compare
Fig.
8]). The same results were
obtained with a PG oligonucleotide
(
24) (data not shown). We
conclude that phosphorylation can
modulate the function of the p53 core
domain, endowing it with
either an exonuclease or a sequence-specific
DNA binding activity.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 9.
Okadaic acid treatment influences p53 exonuclease and
sequence-specific DNA binding activities in opposite manners. High Five
insect cells were infected with recombinant baculovirus coding for p53.
The cells were split, and one half was treated with okadaic acid (OA).
p53 from both samples was purified by metal affinity chromatography.
Column fractions were analyzed by SDS-PAGE (A) and tested for
exonuclease activity (B) and sequence-specific DNA binding (C). Numbers
on the left in panel A are molecular masses in thousands.
|
|
The 30 C-terminal amino acids of p53 are a prime target for regulatory
posttranslational events. In mouse p53, this region
contains the
documented CK II phosphorylation site Ser386, which
also is a putative
site for the cdk7-cyclin H-p36 complex of TFIIH
(
30), and
two putative protein kinase C type II phosphorylation
sites, Ser370 and
Ser372 (
43), which possibly are also a target
for the
cdk7-cyclin H-p36 complex. The C-terminal region also
is a target for
acetylation of p53 by p300 (
38,
55) and for
glycosylation
(
56), with both events activating sequence-specific
DNA
binding of p53. As the C terminus negatively regulates both
sequence-specific DNA binding of p53 and its exonuclease activity,
we
asked how an enhanced phosphorylation status of the C-terminally
truncated p53
1-360 fragment would affect these activities.
In
an experiment performed in parallel to the one shown in Fig.
9,
we
compared the 3'-5' exonuclease and the sequence-specific DNA
binding
activities of the p53
1-360 fragment purified from okadaic
acid-treated and untreated baculovirus-infected insect cells (Fig.
10). Figure
10A shows that this
fragment was obtained in similar
yields and similar purities from both
preparations. In contrast
to the case for full-length p53, okadaic acid
treatment did not
inhibit the exonuclease activity of the
p53
1-360 fragment (Fig.
10B). We conclude that C-terminal
modification negatively regulates
the exonuclease activity of p53,
either directly by phosphorylation
events within the C-terminal region
or indirectly by phosphorylation
of other sites which affect C-terminal
modification. Analysis
of the DNA binding activity of the
p53
1-360 fragment (Fig.
10C)
showed that truncation as such
already significantly enhanced
the DNA binding activity compared to
that of full-length p53 (compare
Fig.
9C and
10C). Enhancing the
phosphorylation status of the p53
1-360 fragment by treating
the culture with okadaic acid further enhanced
its DNA binding activity
towards the
waf1/p21 promoter substrate
in EMSA, in line
with the observation that the phosphorylation
status of the
cyclin-dependent kinase site at Ser309 modulates
sequence-specific DNA
binding of p53 (
66).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 10.
The exonuclease activity of C-terminally truncated p53
is not influenced by okadaic acid treatment. High Five insect cells
were infected with recombinant baculovirus coding for the C-terminally
truncated p531-360 fragment. The cells were split, and one
half was treated with okadaic acid (OA). The p531-360
fragment from both samples was purified by metal affinity
chromatography, analyzed by SDS-PAGE (A), and tested for exonuclease
activity (B) and sequence-specific DNA binding (C). Numbers on the left
in panel A are molecular masses in kilodaltons.
|
|
Binding of p53 to DNA substrates mimicking recombination
intermediates is required for their effective degradation.
We
recently provided evidence that p53 might control fidelity of
homologous recombination by specific mismatch recognition in
heteroduplex recombination intermediates (8). In this study we showed that wt p53, but not mutant p53, binds specifically and with
high affinity to three-stranded DNA substrates mimicking early
recombination intermediates. This interaction also requires an intact
p53 core domain (8). As such substrates probably are
biologically more relevant than the poly(dT) · poly(dA)
substrates normally used in our exonuclease assays, we asked whether
they might serve as effective substrates for the p53 exonucleolytic activity. Furthermore, as the interaction of p53 with such substrates can be analyzed by EMSA, it seemed possible to analyze the connection between substrate binding and exonucleolytic degradation of the substrate by p53 by switching on the p53 exonuclease after substrate binding.
A three-stranded DNA substrate comprising an A-G mismatch and a
radioactively labeled top strand was prepared as described
previously
(
8); its structure is schematically outlined on
the left in
Fig.
11. The substrate then was
incubated with 0, 15,
30, or 60 ng of purified full-length wt p53 in
the absence of
Mg
2+ ions, which are required for activation
of the p53 exonuclease
activity, and the mixture was subjected to PAGE
(Fig.
11, lanes
1 to 4). Two discretely shifted bands were seen in all
fractions
containing p53 (lanes 2 to 4), corresponding to the
interaction
of p53 tetramers (lower band) or higher oligomeric forms of
p53
(upper band) with the substrate. Both shifted bands increased
in
intensity with increasing amounts of p53 added, leading to
a complete
shift of the labeled substrate at the highest p53 concentration
(60 ng)
(Fig.
11, lane 4). In parallel, 5 mM Mg
2+, which is
required for activation of the p53 exonuclease (
48),
was
added to the corresponding mixtures and incubated for 20,
40, 60, and
120 min, and p53-substrate complexes were analyzed
by EMSA (Fig.
11).
It is evident that the Mg
2+-induced exonuclease activity of
p53 led to a rapid, time- and
p53 concentration-dependent degradation
of the p53-bound substrate,
as indicated by the loss of the shifted
bands and the appearance
of a radioactive smear at the bottom of the
gel in those mixtures
containing p53, but not in the one devoid of p53
(lane 5), even
after prolonged incubation (120 min). Most importantly,
the p53
exonuclease activity paralleled the degree of substrate binding
and did not affect the unbound substrate. The slight time-dependent
decrease in the amount of free substrate seen in lanes 12 to 15
reflects the recruitment of new substrate by p53 after complete
digestion of the bound substrate, consistent with the high on-and-off
rates reported by us for this dynamic interaction (
8). We
conclude
that by binding to the three-stranded DNA substrate, p53 forms
an enzyme-substrate complex; the Mg
2+-induced p53
exonuclease activity then leads to rapid degradation
of the p53-bound
substrate.

View larger version (67K):
[in this window]
[in a new window]
|
FIG. 11.
DNA recombination intermediates are degraded
effectively only in complex with p53. Purified wt p53 (0, 15, 30, and
60 ng) was incubated with a three-stranded DNA substrate mimicking an
early recombination intermediate and containing an A-G mismatch
(schematically outlined on the left) in the presence (lanes 5, 7 to 10, 12 to 15, and 17 to 20) or absence (lanes 1 to 4, 6, 11, and 16) of 5 mM Mg2+, which is required for switching on the p53
exonuclease (lanes 6, 11, and 16 are identical to lanes 2, 3, and 4, respectively). Incubation reactions were performed for 20, 40, 60, and
120 min at room temperature. Lanes 1 to 4 show a protein
concentration-dependent shift of the p53-substrate complexes. Addition
of Mg2+ to the binding reaction mixture (lanes 7 to 10, 12 to 15, and 17 to 20) led to complete degradation of the bound (lanes 17 to 20) but not the unbound (lanes 7 to 10 and 12 to 15) substrate in a
time- and p53-dependent fashion. A slight decrease in the amount of
unbound substrate (lanes 12 to 15) reflects the recruitment of new
substrate by p53 after complete digestion of the bound substrate.
|
|
 |
DISCUSSION |
Our analyses of the exonuclease activities of native p53
fragments, expressed in insect cells infected with the respective recombinant baculoviruses and purified by metal affinity
chromatography, demonstrated that the p53 core domain harbors two
different activities, i.e., sequence-specific DNA binding activity and
exonuclease activity. All p53 fragments containing the core domain were
exonuclease positive, whereas all fragments devoid of this domain were
exonuclease negative. In support of this, comparison of the exonuclease
activities of the bacterially expressed core domains from wt p53 and
from MethA mutant p53 showed that only the wt and not the mutant MethA p53 core domain exhibited exonuclease activity. Finally, SV40 T-Ag,
bound to the p531-320 fragment via the p53 core domain, completely inhibited its exonuclease activity, which is even more impressive because the p531-320 fragment exhibited about a
10-fold-higher specific exonuclease activity than full-length p53.
The finding that C-terminal truncation of p53 activated the exonuclease
activity by at least a factor of 10 suggests that the p53 exonuclease
activity is also subject to regulation in vivo. The observed activation
was not due to different protein stabilities of the full-length p53 and
the C-terminally truncated p53 fragments, as purified full-length p53
could be activated in vitro by specific limited proteolytic digestion
with thermolysin, which created p53 fragments lacking the N and C
termini of full-length p53. The strongly enhanced exonuclease activity
of C-terminally truncated p53 fragments also is not due to a more
efficient association of an exogenous exonuclease. When metal
affinity-purified p531-320 protein of already high purity
(>90%) was further purified by two different chromatography steps,
the exonuclease activity always copurified with this p53 fragment. The
purity of the p531-320 protein and the fact that the
exonuclease activity remained associated with this protein during
purification according to quite different separation criteria in all
likelihood exclude an associated exonuclease. We therefore conclude
that the intrinsic exonuclease activity of full-length p53 is
negatively regulated by the basic regulatory domain of p53 comprising
the C-terminal 30 amino acids of the p53 molecule.
Despite a negative regulation of both exonuclease and sequence-specific
DNA binding activities by the p53 C-terminal regulatory domain, these
activities were found to be regulated in different and seemingly
opposing manners on full-length p53. Whereas addition of PAb421
activated p53 binding to the waf1/p21 promoter substrate, the same treatment strongly reduced the p53 exonuclease activity. Similarly, hyperphosphorylation of p53 enhanced its
sequence-specific DNA binding activity but abolished its exonuclease
activity. In this respect, p53 prepared according to protocols
optimized for analyzing sequence-specific DNA binding might be negative
in exonuclease assays and vice versa. Interestingly, the exonuclease
activity of the C-terminally truncated p531-360 fragment
was no longer affected by alterations of its phosphorylation status, in
contrast to sequence-specific DNA binding of the p531-360
fragment, which could still be further activated by enhancing its
phosphorylation status. The most straightforward explanation for the
insensitivity of the exonuclease activity of the p531-360
fragment to hyperphosphorylation is that the exonuclease activity of
full-length p53 is regulated mainly by the phosphorylation status of
the C-terminal phosphorylation site Ser386, Ser370, or Ser372. However,
other possibilities cannot be excluded, since phosphorylation sites in
other regions of the p53 molecule might control posttranslational
modification events within the p53 C terminus and vice versa. Further
experiments in our laboratory are aimed at identifying the
posttranslational modification(s) inhibiting the p53 exonuclease activity.
So far, an experimental differentiation between mechanisms regulating
the exonuclease and the sequence-specific DNA binding activities of
full-length p53 could be achieved only by means that activate
sequence-specific DNA binding but inactivate the exonuclease. However,
it is noteworthy that bacterially expressed, i.e., nonphosphorylated,
p53 is virtually devoid of sequence-specific DNA binding activity
(22, 24) but exerts exonuclease activity (48),
pointing to the possibility that the p53 exonuclease activity might be
exerted by hypo- or even nonphosphorylated p53. The specific targeting
of distinct phosphorylation sites of p53 by PP2A has been described
(53). Furthermore, one could imagine specific dephosphorylation of p53 by other phosphatases. Considering that C-terminal truncation of p53 strongly activated its exonuclease activity, specific in vivo proteolytic cleavage of p53 (46, 50) could also lead to activation. In this regard it is
noteworthy that at least in mouse cells p53 exists in two forms, as a
regularly spliced full-length protein and as an alternatively spliced
p53 missing the C-terminal regulatory domain (33). This
alternatively spliced form of p53 is preferentially expressed in the
G2 phase of the cell cycle (33), i.e., at a time
when the replicated genome is scanned for replication errors prior to
mitosis (62). Finally, p53 can interact with a large number
of cellular proteins (52), which might induce conformational
alterations activating the p53 exonuclease.
We are especially intrigued by the finding that sequence-specific DNA
binding and exonuclease activities seem to be mutually exclusive p53
activities. So far, activation of p53 has been considered a
prerequisite for p53 function, and there even has been the notion that
p53, in the absence of cellular stress, is functionally inactive (64). Stress-mediated activation of p53 function correlates with activation of sequence-specific DNA binding, which in turn correlates with inhibition of the p53 exonuclease activity. Therefore, we hypothesize that p53 in the absence of cellular stress is not an
inactive protein but exerts non-stress-induced functions required for
maintaining genomic integrity, (e.g., repair of spontaneous DNA damage
or the control of homologous recombination) via intrinsic activities
not related to sequence-specific DNA binding (e.g., its exonuclease
activity) (25). In this regard, it recently has been
reported that p53 specifically interacts with DNA polymerase
(32a) and may control fidelity of DNA replication mediated by this enzyme by acting as an external proofreader (21).
To get further clues about a possible in vivo function of the p53
exonuclease, we here followed up our previous observations that p53
negatively regulates homologous recombination, possibly by controlling
fidelity of homologous recombination via specific mismatch recognition
(8, 68). wt p53 specifically binds to three-stranded DNA
substrates mimicking early recombination intermediates and rapidly and
efficiently degrades the bound substrate when the exonuclease activity
of p53 is switched on by addition of Mg2+ as a cofactor. In
addition to suggesting that binding of such a substrate represents the
formation of a relevant enzyme-substrate complex, this finding provides
further independent evidence for the intrinsic nature of the p53
exonuclease: as the exonuclease activity as well as binding of the
three-stranded DNA substrate requires an intact p53 core domain
(8), it is extremely unlikely that an exogenous exonuclease
will associate with the p53 core domain and still allow binding of the
substrate but, on the other hand, will be in a spatial orientation that
allows degradation of the substrate attached to the same p53 molecule.
This conclusion is drawn from our finding that specifically the bound,
and not the unbound, substrate was degraded upon addition of
Mg2+ ions as a cofactor, starting the p53 exonuclease
activity. Regarding the biological relevance of this interaction, it
may be more than a coincidence that binding of SV40 T-Ag to p53
abolished the p53 exonuclease activity in vitro (this study) and
enhanced the frequency of recombination in SV40-infected cells by at
least 1 order of magnitude (68). However, more direct proof
for an in vivo involvement of the p53 exonuclease activity in
recombination or other repair events has to be obtained in order to
substantiate our model of a dual role for p53 in maintaining genomic
integrity (25).
 |
ACKNOWLEDGMENTS |
This work was supported by Deutsche Krebshilfe grant 10-0858-De2,
German Israeli Foundation (G.I.F.) grant 1044-207.03/96, DFG grant Wi
1376/1-2, Boehringer Mannheim, and the Fonds der chemischen Industrie.
F.J. was supported by Boehringer Ingelheim Fonds, Stuttgart, Germany.
The Heinrich-Pette-Institut is financially supported by Freie und
Hansestadt Hamburg and Bundesministerium für Gesundheit.
F.J. and N.A. contributed equally to this work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address:
Heinrich-Pette-Institut für Experimentelle Virologie und
Immunologie an der Universität Hamburg, Martinstr. 53, D-20251
Hamburg, Germany. Phone: 49-40-480 51-261. Fax: 49-40-480 51-117. E-mail: deppert{at}hpi.uni-hamburg.de.
 |
REFERENCES |
| 1.
|
Bakalkin, G.,
G. Selivanova,
T. Yakovleva,
E. Kiseleva,
E. Kashuba,
K. P. Magnusson,
L. Szekely,
G. Klein,
L. Terenius, and K. G. Wiman.
1995.
p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain.
Nucleic Acids Res.
23:362-369[Abstract/Free Full Text].
|
| 2.
|
Bakalkin, G.,
T. Yakovleva,
G. Selivanova,
K. P. Magnusson,
L. Szekely,
E. Kiseleva,
G. Klein,
L. Terenius, and K. G. Wiman.
1994.
p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer.
Proc. Natl. Acad. Sci. USA
91:413-417[Abstract/Free Full Text].
|
| 3.
|
Barak, Y.,
T. Juven,
R. Haffner, and M. Oren.
1993.
mdm2 expression is induced by wild-type p53 activity.
EMBO J.
12:461-468[Medline].
|
| 4.
|
Bargonetti, J.,
J. J. Manfredi,
X. Chen,
D. R. Marshak, and C. Prives.
1993.
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein.
Genes Dev.
7:2565-2574[Abstract/Free Full Text].
|
| 5.
|
Bargonetti, J.,
I. Reynisdottir,
P. N. Friedman, and C. Prives.
1992.
Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.
Genes Dev.
6:1886-1898[Abstract/Free Full Text].
|
| 6.
|
Cho, Y.,
S. Gorina,
P. D. Jeffrey, and N. P. Pavletich.
1994.
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.
Science
265:346-355[Abstract/Free Full Text].
|
| 7.
|
DeLeo, A. B.,
H. Shiku,
T. Takahashi,
M. John, and L. J. Old.
1977.
Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma.
J. Exp. Med.
146:720-734[Abstract/Free Full Text].
|
| 8.
|
Dudenhoeffer, C.,
G. Rohaly,
K. Will,
W. Deppert, and L. Wiesmueller.
1998.
Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination.
Mol. Cell. Biol.
18:5332-5342[Abstract/Free Full Text].
|
| 9.
|
El-Deiry, W. S.,
J. W. Harper,
P. M. O'Connor,
V. E. Velculescu,
C. E. Canman,
J. Jackman,
J. A. Pietenpol,
M. Burrell,
D. E. Hill,
Y. Wang,
K. G. Wiman,
W. E. Mercer,
M. B. Kastan,
K. W. Kohn,
S. J. Elledge,
K. W. Kinzler, and B. Vogelstein.
1994.
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
Cancer Res.
54:1169-1174[Abstract/Free Full Text].
|
| 10.
|
El-Deiry, W. S.,
T. Tokino,
V. E. Velculescu,
D. B. Levy,
R. Parsons,
J. M. Trent,
D. Lin,
W. E. Mercer,
K. W. Kinzler, and B. Vogelstein.
1993.
WAF1, a potential mediator of p53 tumor suppression.
Cell
75:817-825[Medline].
|
| 11.
|
Eliyahu, D.,
N. Goldfinger,
O. Pinhasi-Kimhi,
G. Shaulsky,
Y. Skurnik,
N. Arai,
V. Rotter, and M. Oren.
1988.
Meth A fibrosarcoma cells express two transforming mutant p53 species.
Oncogene
3:313-321[Medline].
|
| 12.
|
Fiscella, M.,
S. J. Ullrich,
N. Zambrano,
M. T. Shields,
D. Lin,
S. P. Lees-Miller,
C. W. Anderson,
W. E. Mercer, and E. Appella.
1993.
Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression.
Oncogene
8:1519-1528[Medline].
|
| 13.
|
Fritsche, M.,
C. Haessler, and G. Brandner.
1993.
Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents.
Oncogene
8:307-318[Medline].
|
| 14.
|
Fuchs, B.,
D. Hecker, and K. H. Scheidtmann.
1995.
Phosphorylation studies on rat p53 using the baculovirus expression system manipulation of the phosphorylation state with okadaic acid and influence on DNA binding.
Eur. J. Biochem.
228:625-639[Medline].
|
| 15.
|
Gannon, J. V.,
R. Greaves,
R. Iggo, and D. P. Lane.
1990.
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
EMBO J.
9:1595-1602[Medline].
|
| 16.
|
Halazonetis, T. D., and A. N. Kandil.
1993.
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants.
EMBO J.
12:5057-5064[Medline].
|
| 17.
|
Hansen, S.,
T. R. Hupp, and D. P. Lane.
1996.
Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins.
J. Biol. Chem.
271:3917-3924[Abstract/Free Full Text].
|
| 18.
|
Harlow, E.,
L. V. Crawford,
D. C. Pim, and N. M. Williamson.
1981.
Monoclonal antibodies specific for simian virus 40 tumor antigens.
J. Virol.
39:861-869[Abstract/Free Full Text].
|
| 19.
|
Harper, J. W.,
G. R. Adami,
M. Wei,
K. Keyomarsi, and S. J. Elledge.
1993.
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Cell
75:805-816[Medline].
|
| 20.
|
Hecker, D.,
G. Page,
M. Lohrum,
S. Weiland, and K. H. Scheidtmann.
1996.
Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs.
Oncogene
12:953-961[Medline].
|
| 21.
|
Huang, P.
1998.
Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein.
Oncogene
17:261-270[Medline].
|
| 22.
|
Hupp, T. R., and D. P. Lane.
1994.
Allosteric activation of latent p53 tetramers.
Curr. Biol.
4:865-875[Medline].
|
| 23.
|
Hupp, T. R.,
D. W. Meek,
C. A. Midgley, and D. P. Lane.
1993.
Activation of the cryptic DNA binding function of mutant forms of p53.
Nucleic Acids Res.
21:3167-3174[Abstract/Free Full Text].
|
| 24.
|
Hupp, T. R.,
D. W. Meek,
C. A. Midgley, and D. P. Lane.
1992.
Regulation of the specific DNA binding function of p53.
Cell
71:875-886[Medline].
|
| 25.
| Janus, F., N. Albrechtsen, I. Dornreiter, L. Wiesmüller, F. Grosse, and W. Deppert. The dual role model
for p53 in maintaining genomic integrity. Cell. Mol. Life Sci., in
press.
|
| 26.
|
Jayaraman, L., and C. Prives.
1995.
Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus.
Cell
81:1021-1029[Medline].
|
| 27.
|
Jiang, D.,
A. Srinivasan,
G. Lozano, and P. D. Robbins.
1993.
SV40 T antigen abrogates p53-mediated transcriptional activity.
Oncogene
8:2805-2812[Medline].
|
| 28.
|
Kastan, M. B.,
Q. Zhan,
W. D. El-Deiry,
F. Carrier,
T. Jacks,
W. V. Walsh,
B. S. Plunkett,
B. Vogelstein, and A. J. Fornace, Jr.
1992.
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.
Cell
71:587-597[Medline].
|
| 29.
|
Kim, E.,
N. Albrechtsen, and W. Deppert.
1997.
DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53.
Oncogene
15:857-869[Medline].
|
| 30.
|
Ko, L. J.,
S. Y. Shieh,
X. B. Chen,
L. Jayaraman,
K. Tamai,
Y. Taya,
C. Prives, and Z. Q. Pan.
1997.
p53 is phosphorylated by Cdk7-cyclin H in a p36mat1-dependent manner.
Mol. Cell. Biol.
17:7220-7229[Abstract].
|
| 31.
|
Kornberg, A., and T. Baker.
1991.
DNA replication, 2nd ed.
W. H. Freeman, San Francisco, Calif.
|
| 32.
|
Kuerbitz, S. J.,
B. S. Plunkett,
W. V. Walsh, and M. B. Kastan.
1992.
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Proc. Natl. Acad. Sci. USA
89:7491-7495[Abstract/Free Full Text].
|
| 32a.
| Kühn, C., F. Müller, C. Meller, H.-P.
Nasheue, F. Janus, W. Deppert, and F. Grosse. Surface plasma
resonance measurements reveal stable complex formation between p53 and
DNA polymerase . Oncogene, in press.
|
| 33.
|
Kulesz-Martin, M. F.,
B. Lisafeld,
H. Huang,
N. D. Kisiel, and L. Lee.
1994.
Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells.
Mol. Cell. Biol.
14:1698-1708[Abstract/Free Full Text].
|
| 34.
|
Lane, D. P.
1993.
Cancer: a death in the life of p53.
Nature
362:786-787[Medline].
|
| 35.
|
Lane, D. P.
1992.
Cancer: p53, guardian of the genome.
Nature
358:15-16[Medline].
|
| 36.
|
Lane, D. P.,
C. W. Stephen,
C. A. Midgley,
A. Sparks,
T. R. Hupp,
D. A. Daniels,
R. Greaves,
A. Reid,
B. Vojtesek, and S. M. Picksley.
1996.
Epitope analysis of the murine p53 tumour suppressor protein.
Oncogene
12:2461-2466[Medline].
|
| 37.
|
Lee, S.,
B. Elenbaas,
A. Levine, and J. Griffith.
1995.
p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches.
Cell
81:1013-1020[Medline].
|
| 38.
|
Lill, N. L.,
S. R. Grossman,
D. Ginsberg,
J. DeCaprio, and D. M. Livingston.
1997.
Binding and modulation of p53 by p300/CBP coactivators.
Nature
387:823-827[Medline].
|
| 39.
|
Linn, S. M.,
R. S. Lloyd, and R. J. Roberts.
1993.
Nucleases, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 40.
|
Lohrum, M., and K. H. Scheidtmann.
1996.
Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Oncogene
13:2527-2539[Medline].
|
| 41.
|
Marx, J.
1993.
How p53 suppresses cell growth.
Science
262:1644-1645[Free Full Text].
|
| 42.
|
Mietz, J. A.,
T. Unger,
J. M. Huibregtse, and P. M. Howley.
1992.
The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein.
EMBO J.
11:5013-5020[Medline].
|
| 43.
|
Milne, D. M.,
L. McKendrick,
L. J. Jardine,
E. Deacon,
J. M. Lord, and D. W. Meek.
1996.
Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate.
Oncogene
13:205-211[Medline].
|
| 44.
|
Miyashita, T., and J. C. Reed.
1995.
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.
Cell
80:293-299[Medline].
|
| 45.
|
Mol, C. D.,
C. F. Kuo,
M. M. Thayer,
R. P. Cunningham, and J. A. Tainer.
1995.
Structure and function of the multifunctional DNA-repair enzyme exonuclease III.
Nature
374:381-386[Medline].
|
| 46.
|
Molinari, M.,
A. L. Okorokov, and J. Milner.
1996.
Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding.
Oncogene
13:2077-2086[Medline].
|
| 47.
|
Muller, C. W., and S. C. Harrison.
1995.
The structure of the NF-kappa B p560:DNA-complex: a starting point for analyzing the Rel family.
FEBS Lett.
369:113-117[Medline].
|
| 48.
|
Mummenbrauer, T.,
F. Janus,
B. Mueller,
L. Wiesmueller,
W. Deppert, and F. Grosse.
1996.
p53 protein exhibits 3'-to-5' exonuclease activity.
Cell
85:1089-1099[Medline].
|
| 49.
|
Oberosler, P.,
P. Hloch,
U. Ramsperger, and H. Stahl.
1993.
p53-catalyzed annealing of complementary single-stranded nucleic acids.
EMBO J.
12:2389-2396[Medline].
|
| 50.
|
Okorokov, A. L.,
F. Ponchel, and J. Milner.
1997.
Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53.
EMBO J.
16:6008-6017[Medline].
|
| 51.
|
Pavletich, N. P.,
K. A. Chambers, and C. O. Pabo.
1993.
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
Genes Dev.
7:2556-2564[Abstract/Free Full Text].
|
| 52.
|
Pietenpol, J. A., and B. Vogelstein.
1993.
Tumor suppressor genes: no room at the p53 inn.
Nature
365:17-18[Medline].
|
| 53.
|
Scheidtmann, K. H.,
M. C. Mumby,
K. Rundell, and G. Walter.
1991.
Dephosphorylation of simian virus 40 large-T antigen and p53 protein by protein phosphatase 2A: inhibition by small-t antigen.
Mol. Cell. Biol.
11:1996-2003[Abstract/Free Full Text].
|
| 54.
|
Schmieg, F. I., and D. T. Simmons.
1988.
Characterization of the in vitro interaction between SV40 T antigen and p53: mapping the p53 binding site.
Virology
164:132-140[Medline].
|
| 55.
|
Scolnick, D. M.,
N. H. Chehab,
E. S. Stavridi,
M. C. Lien,
L. Caruso,
E. Moran,
S. L. Berger, and T. D. Halazonetis.
1997.
CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein.
Cancer Res.
57:3693-3696[Abstract/Free Full Text].
|
| 56.
|
Shaw, P.,
J. Freeman,
R. Bovey, and R. Iggo.
1996.
Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus.
Oncogene
12:921-930[Medline].
|
| 57.
|
Slingerland, J. M.,
J. R. Jenkins, and S. Benchimol.
1993.
The transforming and suppressor functions of p53 alleles: Effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.
EMBO J.
12:1029-1037[Medline].
|
| 58.
|
Stephen, C. W.,
P. Helminen, and D. P. Lane.
1995.
Characterization of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions.
J. Mol. Biol.
248:58-78[Medline].
|
| 59.
|
Stephen, C. W., and D. P. Lane.
1992.
Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library.
J. Mol. Biol.
225:577-583[Medline].
|
| 60.
|
Stürzbecher, H. W.,
R. Brain,
C. Addison,
K. Rudge,
M. Remm,
M. Grimaldi,
E. Keenan, and J. R. Jenkins.
1992.
A C-terminal a-helix plus basic region motif is the major structural determinant of p53 tetramerization.
Oncogene
7:1513-1523[Medline].
|
| 61.
|
Tarunina, M., and J. R. Jenkins.
1993.
Human p53 binds DNA as a protein homodimer but monomeric variants retain full transcription transactivation activity.
Oncogene
8:3165-3173[Medline].
|
| 62.
|
Tavormina, P. A.,
Y. Wang, and D. J. Burke.
1997.
Differential requirements for DNA replication in the activation of mitotic check points in Saccharomyces cerevisiae.
Mol. Cell. Biol.
17:3315-3322[Abstract].
|
| 63.
|
Unger, T.,
J. A. Mietz,
M. Scheffner,
C. L. Yee, and P. M. Howley.
1993.
Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition, and transformation suppression.
Mol. Cell. Biol.
13:5186-5194[Abstract/Free Full Text].
|
| 64.
|
Vogelstein, B., and K. W. Kinzler.
1992.
p53 function and dysfunction.
Cell
70:523-526[Medline].
|
| 65.
|
Wade-Evans, A., and J. R. Jenkins.
1985.
Precise epitope mapping of the murine transformation-associated protein, p53.
EMBO J.
4:699-706[Medline].
|
| 66.
|
Wang, Y., and C. Prives.
1995.
Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases.
Nature
376:88-91[Medline].
|
| 67.
|
Wang, Y.,
M. Reed,
P. Wang,
J. E. Stenger,
G. Mayr,
M. E. Anderson,
J. F. Schwedes, and P. Tegtmeyer.
1993.
p53 domain: identification and characterization of two autonomous DNA-binding regions.
Genes Dev.
7:2575-2586[Abstract/Free Full Text].
|
| 68.
|
Wiesmüller, L.,
J. Cammenga, and W. Deppert.
1996.
In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes.
J. Virol.
70:737-744[Abstract].
|
| 69.
|
Wu, X.,
J. H. Bayle,
D. Olson, and A. J. Levine.
1993.
The p53-mdm-2 autoregulatory feedback loop.
Genes Dev.
7:1126-2232[Abstract/Free Full Text].
|
| 70.
|
Yewdell, J. W.,
J. V. Gannon, and D. P. Lane.
1986.
Monoclonal antibody analysis of p53 expression in normal and transformed cells.
J. Virol.
59:444-452[Abstract/Free Full Text].
|
Molecular and Cellular Biology, March 1999, p. 2155-2168, Vol. 19, No. 3
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wong, T. S., Rajagopalan, S., Townsley, F. M., Freund, S. M., Petrovich, M., Loakes, D., Fersht, A. R.
(2009). Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53. Nucleic Acids Res
37: 568-581
[Abstract]
[Full Text]
-
Jung, J. K., Kwun, H. J., Lee, J.-O., Arora, P., Jang, K. L.
(2007). Hepatitis B virus X protein differentially affects the ubiquitin-mediated proteasomal degradation of beta-catenin depending on the status of cellular p53. J. Gen. Virol.
88: 2144-2154
[Abstract]
[Full Text]
-
Zurer, I., Hofseth, L. J., Cohen, Y., Xu-Welliver, M., Hussain, S. P., Harris, C. C., Rotter, V.
(2004). The role of p53 in base excision repair following genotoxic stress. Carcinogenesis
25: 11-19
[Abstract]
[Full Text]
-
Wolcke, J., Reimann, M., Klumpp, M., Gohler, T., Kim, E., Deppert, W.
(2003). Analysis of p53 "Latency" and "Activation" by Fluorescence Correlation Spectroscopy: EVIDENCE FOR DIFFERENT MODES OF HIGH AFFINITY DNA BINDING. J. Biol. Chem.
278: 32587-32595
[Abstract]
[Full Text]
-
Brazdova, M., Palecek, J., Cherny, D. I., Billova, S., Fojta, M., Pecinka, P., Vojtesek, B., Jovin, T. M., Palecek, E.
(2002). Role of tumor suppressor p53 domains in selective binding to supercoiled DNA. Nucleic Acids Res
30: 4966-4974
[Abstract]
[Full Text]
-
Nilsen, H., Krokan, H. E.
(2001). Base excision repair in a network of defence and tolerance. Carcinogenesis
22: 987-998
[Full Text]